Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LumiraDx Limited - Common stock (NQ:LMDX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about LumiraDx Limited - Common stock

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
From LumiraDx Inc
Via GlobeNewswire
Stocks Commence 2024 Bullish Rally: LMDX, HNRC, BULT, HALB, SPZI
Via AB Newswire
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Reports Second Quarter 2023 Results
From LumiraDx Inc
Via GlobeNewswire
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
From LumiraDx Inc
Via GlobeNewswire
LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany 
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraDx... 
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Reports First Quarter 2023 Results
From LumiraDx Inc
Via GlobeNewswire
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
From LumiraDx Inc
Via GlobeNewswire
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
From LumiraDx Inc
Via GlobeNewswire
LumiraDx to Present at Raymond James Institutional Investors Conference
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test’s ongoing development and future launch into developing countries 
From LumiraDx Inc
Via GlobeNewswire
Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” 
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa 
From LumiraDx Inc
Via GlobeNewswire
LumiraDx Reports Third Quarter 2022 Results
Progress on Near-Term Growth Opportunities and Cost Savings 
From LumiraDx Inc
Via GlobeNewswire
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
From LumiraDx Inc
Via GlobeNewswire
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
From CA Healthcare Acquisition Corp.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.